Search Results

There are 7505 results for: content related to: A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent

  1. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 7, July 2011, Pages: 604–614, C. G. Patel, D. Kornhauser, N. Vachharajani, B. Komoroski, E. Brenner, M. Handschuh del Corral, L. Li and D. W. Boulton

    Article first published online : 24 MAY 2011, DOI: 10.1111/j.1463-1326.2011.01381.x

  2. You have free access to this content
    Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 72, Issue 1, July 2011, Pages: 92–102, Vijay V. Upreti, David W. Boulton, Li Li, Agatha Ching, Hong Su, Frank P. LaCreta and Chirag G. Patel

    Article first published online : 9 JUN 2011, DOI: 10.1111/j.1365-2125.2011.03937.x

  3. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 6, June 2011, Pages: 523–532, M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower, I. Gause-Nilsson and for the D1680C00007 Investigators

    Article first published online : 20 APR 2011, DOI: 10.1111/j.1463-1326.2011.01382.x

  4. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 6, June 2011, Pages: 567–576, A. Pfützner, E. Paz-Pacheco, E. Allen, R. Frederich, R. Chen and for the CV181039 Investigators

    Article first published online : 20 APR 2011, DOI: 10.1111/j.1463-1326.2011.01385.x

  5. You have free access to this content
    Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 6, June 2009, Pages: 611–622, M. Jadzinsky, A. Pfützner, E. Paz-Pacheco, Z. Xu, E. Allen, R. Chen and CV181-039 Investigators

    Article first published online : 6 MAY 2009, DOI: 10.1111/j.1463-1326.2009.01056.x

    Corrected by:

    Erratum

    Vol. 12, Issue 5, 462, Article first published online: 30 MAR 2010

  6. Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 50, Issue 10, October 2010, Pages: 1211–1216, Chirag G. Patel, Jenny Zhang, Li Li, Lara Gooding, Robert Croop, Tong Li and David W. Boulton

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009360532

  7. A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin

    The Journal of Clinical Pharmacology

    Volume 52, Issue S1, January 2012, Pages: 126S–133S, Dr. Liping Zhang, Dr. David W. Boulton and Dr. Marc Pfister

    Article first published online : 23 APR 2013, DOI: 10.1177/0091270011415627

  8. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

    Diabetes/Metabolism Research and Reviews

    Volume 30, Issue 7, October 2014, Pages: 556–569, Boaz Hirshberg, Artist Parker, Helen Edelberg, Mark Donovan and Nayyar Iqbal

    Article first published online : 15 OCT 2014, DOI: 10.1002/dmrr.2502

  9. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 7, July 2015, Pages: 630–638, G. Schernthaner, S. Durán-Garcia, M. Hanefeld, G. Langslet, L. Niskanen, C. J. Östgren, E. Malvolti and E. Hardy

    Article first published online : 7 APR 2015, DOI: 10.1111/dom.12461

  10. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 8, August 2010, Pages: 648–658, A. J. Scheen

    Article first published online : 27 FEB 2010, DOI: 10.1111/j.1463-1326.2010.01212.x

  11. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 5, May 2008, Pages: 376–386, J. Rosenstock, S. Sankoh and J. F. List

    Article first published online : 18 MAR 2008, DOI: 10.1111/j.1463-1326.2008.00876.x

  12. You have full text access to this OnlineOpen article
    Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects

    Pharmacology Research & Perspectives

    Volume 3, Issue 6, December 2015, Blisse Vakkalagadda, Marion L. Vetter, Jignasa Rana, Charles H. Smith, Jian Huang, Jennifer Karkas, David W. Boulton and Frank LaCreta

    Article first published online : 12 JAN 2016, DOI: 10.1002/prp2.201

  13. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

    Diabetes, Obesity and Metabolism

    Volume 17, Issue 5, May 2015, Pages: 487–494, G. Leibowitz, A. Cahn, D. L. Bhatt, B. Hirshberg, O. Mosenzon, C. Wei, G. Jermendy, W. H.-H. Sheu, J. L. Sendon, K. Im, E. Braunwald, B. M. Scirica and I. Raz

    Article first published online : 25 FEB 2015, DOI: 10.1111/dom.12445

  14. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 6, June 2012, Pages: 481–492, K. R. Gerrald, E. Van Scoyoc, R. C. Wines, T. Runge and D. E. Jonas

    Article first published online : 27 DEC 2011, DOI: 10.1111/j.1463-1326.2011.01540.x

  15. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 9, September 2011, Pages: 850–858, R. R. Henry, S. R. Smith, S. L. Schwartz, S. R. Mudaliar, C. F. Deacon, J. J. Holst, R. Y. Duan, R. S. Chen and J. F. List

    Article first published online : 26 JUL 2011, DOI: 10.1111/j.1463-1326.2011.01417.x

  16. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 11, November 2012, Pages: 1202–1215, Vincent Lo Re III, Kevin Haynes, Eileen E. Ming, Jennifer Wood Ives, Laura N. Horne, Kimberly Fortier, Dena M. Carbonari, Sean Hennessy, Serena Cardillo, Peter P. Reese, K. Rajender Reddy, David Margolis, Andrea Apter, Stephen E. Kimmel, Jason Roy, Cristin P. Freeman, Hanieh Razzaghi, Crystal N. Holick, Daina B. Esposito, Tjeerd-Pieter Van Staa, Harshvinder Bhullar and Brian L. Strom

    Article first published online : 4 JUL 2012, DOI: 10.1002/pds.3318

  17. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 1, January 2011, Pages: 7–18, C. F. Deacon

    Article first published online : 28 NOV 2010, DOI: 10.1111/j.1463-1326.2010.01306.x

  18. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

    Diabetes/Metabolism Research and Reviews

    Volume 26, Issue 7, October 2010, Pages: 540–549, André J. Scheen, Guillaume Charpentier, Carl Johan Östgren, Åsa Hellqvist and Ingrid Gause-Nilsson

    Article first published online : 7 SEP 2010, DOI: 10.1002/dmrr.1114

  19. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

    International Journal of Clinical Practice

    Volume 65, Issue 12, December 2011, Pages: 1230–1239, M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, I. Gause-Nilsson and K-M. Schützer

    Article first published online : 7 OCT 2011, DOI: 10.1111/j.1742-1241.2011.02812.x

  20. You have full text access to this OnlineOpen article
    Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

    International Journal of Clinical Practice

    Volume 63, Issue 9, September 2009, Pages: 1395–1406, A. R. Chacra, G. H. Tan, A. Apanovitch, S. Ravichandran, J. List, R. Chen and for the CV181-040 Investigators

    Article first published online : 15 JUL 2009, DOI: 10.1111/j.1742-1241.2009.02143.x

    Corrected by:

    Erratum

    Vol. 64, Issue 2, 277, Article first published online: 11 DEC 2009